Image via Wikipedia
Immune Design is the latest company to try and ride the adaptive immune response wave. Their approach is to create vaccines that: “use novel adjuvants and target dendritic cells.” Well, that’s instructive. The fledgling company has three employees and has just raised a hefty $18M in series A funding from Alta Partners, The Column Group and Versant.
I’m not sure what this means, exactly, but apparently all of the dozen or so rock star scientists associated with the company are excited. The press release reads like Dick Schapp book… 3 of the 7 paragraphs are just names of the famous scientists closely associated with the company. Name dropping doesn’t impress me.
The press release also indicates human trials within a year, so it seems that they have the petal to the floor. To me, it screams of quick exit by M&A, but of course, you never know.
> Read the press release here (PR Newswire)
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)